GSK (NYSE:GSK) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

GSK PLC Sponsored ADR (NYSE:GSK) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $43.95 and traded as high as $50.57. GSK shares last traded at $50.3550, with a volume of 4,220,452 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Barclays cut GSK from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, January 6th. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a research report on Monday, October 27th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a research note on Friday, January 16th. Cfra set a $53.00 price target on shares of GSK in a research report on Thursday, October 30th. Finally, HSBC reiterated a “reduce” rating on shares of GSK in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Reduce” and an average price target of $44.13.

GSK Trading Up 2.5%

The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.55 and a current ratio of 0.84. The stock has a market cap of $102.64 billion, a price-to-earnings ratio of 14.22, a price-to-earnings-growth ratio of 1.45 and a beta of 0.45. The company’s 50 day simple moving average is $48.69 and its two-hundred day simple moving average is $43.95.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a net margin of 17.16% and a return on equity of 48.64%. The business had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. During the same period in the previous year, the company posted $0.50 EPS. GSK’s revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 8th. Stockholders of record on Friday, November 14th were issued a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Friday, November 14th. GSK’s payout ratio is currently 48.02%.

Insider Activity at GSK

In other news, major shareholder Plc Gsk purchased 1,470,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the purchase, the insider owned 18,245,691 shares in the company, valued at $346,668,129. This represents a 8.76% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.00% of the company’s stock.

Institutional Trading of GSK

A number of institutional investors have recently added to or reduced their stakes in GSK. Fisher Asset Management LLC grew its position in GSK by 4.4% in the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock worth $1,203,395,000 after acquiring an additional 1,306,590 shares in the last quarter. Quantbot Technologies LP raised its holdings in shares of GSK by 184.6% during the 2nd quarter. Quantbot Technologies LP now owns 138,898 shares of the pharmaceutical company’s stock valued at $5,334,000 after purchasing an additional 90,097 shares in the last quarter. Sound Income Strategies LLC lifted its stake in shares of GSK by 7.3% in the 2nd quarter. Sound Income Strategies LLC now owns 431,256 shares of the pharmaceutical company’s stock valued at $16,560,000 after purchasing an additional 29,197 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of GSK by 28.2% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after purchasing an additional 26,685 shares during the last quarter. Finally, Bard Financial Services Inc. boosted its holdings in GSK by 17.4% in the third quarter. Bard Financial Services Inc. now owns 158,145 shares of the pharmaceutical company’s stock worth $6,826,000 after purchasing an additional 23,400 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.